Clinical Trials

Molecular Landscape and Therapeutic Strategies against Colorectal Cancer

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Aakash Patel April 27, 2024 Cancers (Basel). 2024 Apr 18;16(8):1551. doi: 10.3390/cancers16081551. ABSTRACT Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide. Although the overall incidence of CRC is decreasing, the incidence of young-onset CRC, characterized by a diagnosis of CRC before age 50, is increasing. Outcomes for CRC patients are improving,…
Read more →
The Prognostic Value of the Systemic Immune-Inflammation Index (SII) and Red Cell Distribution Width (RDW) in Patients with Cervical Cancer Treated Using Radiotherapy

27 апреля, 2024

Adverse effects, AI, Clinical outcomes, Clinical research, Clinical study, Clinical trials, Control arm, Data collection, Double-blind, Drug trial, Efficacy, Patient consent, Patient enrollment, Placebo, Randomization, Regulatory approval, Safety profile, Study design, Study protocol, Treatment group, Trial monitoring, Trial phase

Emilia Staniewska April 27, 2024 Cancers (Basel). 2024 Apr 18;16(8):1542. doi: 10.3390/cancers16081542. ABSTRACT INTRODUCTION: There is growing interest in the prognostic value of routinely performed pre-treatment blood test indices, such as the RDW or SII, with the latter combining the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). These indices were shown to be prognostic for…
Read more →

Molecular Landscape and Therapeutic Strategies against Colorectal Cancer

The Prognostic Value of the Systemic Immune-Inflammation Index (SII) and Red Cell Distribution Width (RDW) in Patients with Cervical Cancer Treated Using Radiotherapy